Drugs / BMS-955176
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT02715479 | Apr → May 2016 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02578277 | Nov → Dec 2015 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02576119 | Oct 2015 → Feb 2016 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 1 | NCT02273947 | Oct 2014 → Aug 2016 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02206711 | Aug → Sep 2014 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02157467 | Jun → Aug 2014 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 1 | NCT02095886 | Mar → Jul 2014 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02386098 | Jul 2015 → Jun 2017 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 2 | NCT02415595 | May 2015 → May 2016 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 2 | NCT01803074 | Apr 2013 → Nov 2014 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02608918 Background | Jan → May 2016 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2015-10-23 | Bristol-Myers Squibb | Results Complete Phase 2a Study of HIV-1 Investigational Maturation Inhibitor Demonstrates Positive Results for Therapy Designed to Attack Virus Differently Than Existing Treatments bms.com ↗
Bristol-Myers Squibb Company (NYSE:BMY) today announced overall antiviral activity and safety results from the three-part Phase 2a proof-of-concept study of BMS-955176, a novel investigational therapy designed to prevent the maturation of HIV-1. |
| 2015-07-21 | Bristol-Myers Squibb | Results Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Continued Development bms.com ↗ |
| 2015-02-26 | Bristol-Myers Squibb | Results Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in Preventing Viral Replication via Different Mechanism of Action Than Current Therapies bms.com ↗
The study’s primary endpoint of change in HIV-1 RNA from baseline to Day 11 of greater than -1 log 10 c/mL in HIV-1 RNA was met. |
All press releases naming this drug 3 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS 955176 | “A single dose of \[14C\] BMS 955176 on Day 1 with ND placement 1 hour post dose to facilitate continuous bile collection though 8 hours post dose.” NCT02206711 ↗ |
| Known as | GSK3532795 | “A Phase 2b Randomized, Active-Controlled, Staged, Open-Label Trial to Investigate Safety and Efficacy of BMS-955176/GSK3532795 in Combination With Dolutegravir and Atazanavir...” NCT02386098 ↗1“GSK3532795 (formerly known as BMS-955176) is a second-generation maturation inhibitor targeting a specific Gag cleavage site between capsid p24 and spacer peptide 1 of HIV-1.” PMID 30352054 ↗ Oct 2018 |
| Action | Inhibit | “HIV Maturation Inhibitor” NCT02386098 ↗ |
| Modality | Other / unclassified | “GSK3532795 (formerly known as BMS-955176) is a second-generation maturation inhibitor” PMID 30352054 ↗ Oct 2018 |
| Route | Oral | “BMS-955176 5 mg solution by mouth once daily for 10 days” NCT01803074 ↗ |